Correspondence 0001193125-25-327040 from Ovid Therapeutics Inc. (OVID)
Ovid Therapeutics Inc.
Date: Dec. 19, 2025 · CIK: 0001636651 · Accession: 0001193125-25-327040
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-292151
Letter
Ovid Therapeutics Inc.
441 Ninth Avenue, 14th Floor
New York, New York 10001
December 19, 2025
VIA EDGAR
Division of Corporation Finance
Office of Technology
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
RE: Ovid Therapeutics Inc.
Registration Statement on Form S-3
File No. 333-292151
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Exchange Act of 1933, as amended, Ovid Therapeutics Inc. (the “Registrant”) hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective on December 22, 2025, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable or at such later time as the Registrant may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes each of Laura Berezin and Jaime L. Chase of Cooley LLP, counsel to the Registrant, to make such request on its behalf.
Once the Registration Statement has been declared effective, please orally confirm that event with Jaime L. Chase at (202) 728-7096, or in her absence, Laura Berezin of Cooley LLP, counsel to the Registrant, at (650) 843-5128.
Very truly yours,
OVID THERAPEUTICS INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Ovid Therapeutics Inc. 441 Ninth Avenue, 14th Floor New York, New York 10001 December 19, 2025 VIA EDGAR Division of Corporation Finance Office of Technology United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 RE: Ovid Therapeutics Inc. Registration Statement on Form S-3 File No. 333-292151 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Exchange Act of 1933, as amended, Ovid Therapeutics Inc. (the “Registrant”) hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective on December 22, 2025, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable or at such later time as the Registrant may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes each of Laura Berezin and Jaime L. Chase of Cooley LLP, counsel to the Registrant, to make such request on its behalf. Once the Registration Statement has been declared effective, please orally confirm that event with Jaime L. Chase at (202) 728-7096, or in her absence, Laura Berezin of Cooley LLP, counsel to the Registrant, at (650) 843-5128. Very truly yours, OVID THERAPEUTICS INC. By: /s/ Jeff Rona Name: Jeff Rona Title: Chief Business and Chief Financial Officer cc: Jeff Rona, Ovid Therapeutics Inc. Laura Berezin, Cooley LLP Jaime L. Chase, Cooley LLP